Breast cancer stem cells wear a cell surface protein that is part nametag and part bull’s eye, identifying them as potent tumor-generating cells and flagging their vulnerability to a drug, researchers at The University of Texas MD Anderson Cancer Center report online in Journal of Clinical Investigation.
“We’ve discovered the first single marker for breast cancer stem cells and also found that it’s targetable with a small molecule drug that inhibits an enzyme crucial to its synthesis,” said co-senior author Michael Andreeff, M.D., Ph.D., professor in MD Anderson’s Departments of Leukemia and Stem Cell Transplantation and Cellular Therapy.
Andreeff and colleagues are refining the drug as a potential targeted therapy for breast cancer stem cells, which are thought to be crucial to therapy resistance, disease progression and spread to other organs.








